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ABSTRACT 
 
RNAi can mediate allele-specific silencing, and offers an attractive approach for treatment of human diseases 
caused by dominant, gain-of-function gene mutations. However, allele-specific silencing requires that the 
RNAi target the mutated region of the mRNA, limiting the choices of the target sequences. This often results 
in the use of a suboptimal siRNAs or shRNAs. Unfavorable strand asymmetry, which leads to the sense 
strand rather than the antisense strand to be incorporated into RNA-induced silencing complex (RISC), can 
cause poor RNAi efficacy. We systematically tested an approach that places mismatches at or near the 5’ of 
the antisense strand to create favorable strand asymmetry. Here we show that this approach can enhance the 
RNAi efficacy of not only siRNAs but also shRNAs synthesized from genes, which can be placed in various 
viral vectors. Thus, this design of asymmetric shRNAs could be potentially used in silencing dominant, gain-
of-function gene mutations for gene therapy. 
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INTRODUCTION 
 
RNAi  is  a  conserved  eukaryotic  mechanism  that  is 
triggered  by  the  presence  of  double  stranded  RNA 
(dsRNA) in cells. In RNAi, long dsRNA or hairpin RNA 
are  processed  by  Dicer,  an  enzyme  of  the  RNase  III 
family, into 21-25 nucleotide double-stranded fragments, 
termed small interfering RNAs (siRNAs) (Zamore et al, 
2000;  Bernstein  et  al,  2001).  The  siRNAs  interact  with 
proteins Dicer  and  TRBP  (R2D2  in  Drosophila),  which 
facilitate the formation of a siRNA/multi-protein complex 
called  RISC  (RNA-induced  silencing  complex)  loading 
complex  (RLC)  (Tomari  et  al,  2004).  The  RLC  then 
interacts with additional proteins including Ago2 to form 
the active RISC that contains one of the two siRNA strand 
(called  the  guide  strand).  This  RISC  is  capable  of 
recognizing the target RNA by Watson-Crick base pairing 
with the guide strand and cleaves the target RNA, which is 
then released, and  the RISC  goes  on to catalyze  a  new 
cycle  of  target  recognition  and  cleavage  (Tomari  and 
Zamore, 2005). 
 
RNAi  can  also  be  triggered  by  microRNAs  (miRNAs), 
which  are  synthesized  by  RNA  polymerase  II  and  are 
embedded in long transcripts, called pri-miRNA (Bracht et 
al, 2004; Cai et al, 2004; Lee et al, 2004). Pri-miRNA is 
processed  by  RNase  III  enzyme  Drosha  and  its  partner 
Pasha to form pre-miRNA, which is ~70 nt long and folds 
into a hairpin structure (Lee et al, 2003; Denli et al, 2004.). 
It is then exported by Exportin 5 from the nucleus to the  
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cytoplasm (Yi et al, 2003; Bohnsack et al, 2004; Lund et al, 
2004; Zeng and Cullen, 2004), where it is further processed 
to  form  single  stranded  miRNA  (Grishok  et  al,  2001; 
Hutvagner  et  al,  2001;  Jiang  et  al,  2005;  Ketting  et  al, 
2001; Forstemann et al, 2005). This processing step may be 
tightly  coupled  with  loading  the  miRNA  into  the  RISC, 
which is capable of either cleaving the target RNA (if the 
target perfectly complements the miRNA in sequence) or 
mediating  translational  silencing  (if the  miRNA  contains 
mismatches to multiple sequences in the target RNA).  This 
process has been mimicked by shRNAs synthesized from 
either  Pol III  or  Pol  II  promoters  (Xia  et  al,  2002;  Shi, 
2003; Zeng and Cullen, 2003; Zhou et al, 2005).  
 
Because of its sequence specificity, RNAi has become a 
powerful tool in reverse genetics for investigation of gene 
function. In addition, it has been increasingly applied as a 
therapeutic strategy in cells, animals and even in humans 
(Uprichard,  2005).  In  these  applications,  RNAi  is 
delivered  as  either  synthetic  siRNAs  or  gene-based 
synthesis of shRNAs that mimics pre-miRNAs in structure 
and  function.    However,  silencing  efficacy  of  many 
siRNAs  is  variable  (Khvorova  et  al,  2003;  Hsieh  et  al, 
2004;  Reynolds et al, 2004) and the specificity of RNAi is 
imperfect (Jackson et al, 2003). In research applications 
these are not serious problems because one can screen for 
effective siRNAs and avoid the ones with poor efficacy or 
specificity. However, in therapeutic applications this may 
be problematic. For example, in situations where silencing 
a  mutant  allele  is  therapeutic  but  silencing  a  wild  type 
gene may lead to serious toxicity, selective silencing of the 
mutant allele will be required. To accomplish this siRNAs 
targeting the mutation site must be used (Abdelgany et al, 
2003;  Ding  et  al,  2003;  Gonzalez-Alegre  et  al,  2003; 
Miller et al, 2003; Miller et al, 2004).  Consequently one 
may be forced to select siRNAs within a limited repertoire 
of sequences. 
 
Several hypotheses have been proposed for poor siRNA 
efficacy. Studies have demonstrated that factors such as 
high  GC  content  of  siRNA  (Amarzguioui  et  al,  2004; 
Chalk  et  al,  2004;  Reynolds  et  al,  2004;  Holen  et  al, 
2005), the inaccessibility of the target region (Holen et al, 
2002;  Brown  et  al,  2005;  Heale  et  al,  2005),  and  the 
unfavorable strand asymmetry of the siRNA (Khvorova et 
al,  2003;  Schwarz  et  al,  2003)  could  lead  to  lower 
function of RNAi. While other theories remain disputable, 
the asymmetry rule in RNAi seems well-accepted and is 
perhaps the most dominant factor. The strand asymmetry 
is defined as follows:  For each siRNA, only one of the 
two  strands,  the  guide  strand,  will  be  loaded  into  the 
RISC  and  execute  RNAi.  The  other  strand,  called 
passenger strand, will be destroyed.  The thermodynamic 
stability  of  base  pairing  at  the  two  ends  of  the  siRNA 
predicts the likelihood of which strand will become the 
guide or the passenger strand.  The strand with its 5′ base 
pairing  less  stable  then  its  3′  base  pairing  is  more 
probable to enter RISC and vice versa. If the base pairing 
at  the  two  ends  has  similar  stability,  then  both  strands 
may  enter  RISC  with  similar  probabilities  and  mediate 
RNAi  with  similar  potencies.  Therefore,  those  siRNAs 
with stability of their end base pairing favoring the sense 
strands  (as  opposed  to  the  antisense  strand  that  is 
complementary to the intended target) to enter the RISC 
will  have  poor  RNAi efficacy,  thus  having  unfavorable 
asymmetry. 
 
Strand asymmetry can also affect RNAi specificity.  RNAi 
can silence unintended targets, albeit to a lesser degree than 
the intended one.  This is called off-target effects (Jackson 
et  al,  2003).  Because  the  critical  binding  energy  of  the 
RISC to the target RNA resides in the 5′ half of the guide 
strand (Haley and Zamore, 2004), homology between this 
region of the guide strand and other unintended RNAs can 
lead  to  off-target  silencing  (Jackson  et  al,  2003).  This 
implies that, if  both  strands of the  siRNA  can  enter  the 
RISC, the probability of off-target silencing will increase.  
Thus, by programming the asymmetry into the design of 
siRNA so that only the selected strand enters the RISC, the 
probability of off-target effects is likely to decrease. 
 
Previous siRNAs design strategies have focused on target 
regions  where  natural  asymmetric  siRNAs can  be found 
(Reynolds et al, 2004; Chalk et al, 2005).  This approach 
may not be helpful in situations where the target region is 
confined  (e.g.,  where  RNAi  is  need  for  silencing  the 
expression of a mutated gene specifically), and within this 
confined region no favorably asymmetric siRNAs can be 
found.    In  these  situations,  weakening  base  pairing  by 
incorporation of mismatches at the 5’ of the intended guide 
strand can create strand asymmetry favoring the intended 
guide strand (Holen et al, 2002; Schwarz et al, 2003; Holen 
et al, 2005; Uprichard, 2005; Schwarz et al, 2006). In this 
study, we tested the effectiveness of this design strategy in 
converting  siRNAs  with  unfavorable  asymmetry  to  the 
ones with favorable asymmetry in human cells. We show 
that this strategy can effectively convert a strand of siRNA 
that is originally favored to become the passenger strand to 
the one that is favored to become the guide strand and vice 
versa,  and  this  conversion  enhances  RNAi  efficacy.  
Furthermore,  we  show  that  this  strategy  can  be 
incorporated  into  the  design  of  shRNA  and  enhance  its 
RNAi efficacy and strand specificity. 
 
MATERIALS AND METHODS 
 
siRNA and shRNA preparation 
Single stranded RNAs were purchased from Dharmacon 
Research,  deprotected  according  to  the  manufacturer’s 
instructions, and annealed as described previously (Ding et 
al, 2003). To construct the shRNA vectors, the two strands 
of  synthetic  DNA  oligonucleotides  were  annealed,  and 
subcloned  into  a  RNA  polymerase  III  promoter  (U6) 
driven vector using the restriction sites Pme I and Pst I. 
The parent U6  vector was generated  by cloning the U6 
promoter (-315 to +1) from pmU6 plasmid into Bluescript 
(Sui et al, 2002). The DNA strands contained 19 or 21 nt 
sense  and  antisense  strands  (that  matches  the  target 
sequences)  linked  by  a  9-nucleotide  loop 
(UUCAAGAGA).    The  sense  strand  terminates  with  5 
consecutive  Thymidines  (TTTTT).  All  constructs  were 
verified by nucleotide sequencing.  
 
Cell culture and transfection 
Human  embryonic  kidney  293  cells  were  maintained  in 
Dulbecco’s  Modified  Eagle  Media  (Invitrogen)  
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supplemented  with  10%  (v/v)  FBS  plus  100  U/ml 
penicillin and 100 µg/ml streptomycin. Twenty-four hours 
before  experiments,  cells  were  detached  with  trypsin-
EDTA (0.05% (w/v) Trypsin, 0.53mM EDTA•4Na) at 70-
90%  confluency,  and  transferred  into  the  wells  of 
appropriate plates at 30% cell density. Transfection was 
performed  using  Lipofectamine  2000  (Invitrogen) 
following the manufacturer’s instructions on the following 
day.  For  testing  siRNAs,  the  following  constructs  and 
concentrations  were  used  in  transfection:  The  firefly 
luciferase  (pGL2  control  vector,  Promega)  with  target 
sequence  inserted  into  the  3’  UTR,  2.0  µg/ml;  Renilla 
luciferase  vector  (pRL-TK,  Promega),  0.1  µg/ml;  and 
siRNA, 0.002 to 31.25 nM. For testing shRNA-expressing 
constructs,  the  following  constructs  and  concentrations 
were used in transfection: The target firefly luciferase, 1.0 
µg/ml; Renilla luciferase vector (pRL-TK, Promega), 0.1 
µg/ml, and shRNA-expression vector, 0.5 µg/ml. 
 
Dual luciferase assay 
A modified dual luciferase system (Promega) was used to 
quantify  RNAi  efficiency  in  cell  culture.  To  generate 
specific luciferase target vectors for this study, a synthetic 
double-stranded oligonucleotide containing the restriction 
sites Nde I and Spe I was first engineered into the 3’ UTR 
of  the  firefly  luciferase  vector  (pGL2  control  vector, 
Promega)  at  the  Pf1MI  site.    Subsequently,  a  39  nt 
fragment  of  human  Cu  Zn  superoxide  dismutase  (sod1) 
gene  (sense  strand  5’-aggcatgttggagacttgggcaatgtgactgct 
gacaaa-3’,  antisense  strand  5’-tttgtcagcagtcacattgcccaag 
tctccaacatgcct-3’)  was  synthesized,  annealed  and  cloned 
into the 3’ UTR region of firefly luciferase vector either as 
natural  sense-to-antisense  (sense  target)  or  reversed 
antisense-to-sense  (antisense  target)  oligonucleotide 
duplex  using  the  Nde  I  and  Spe  I  sites.  The  modified 
firefly  luciferase  vectors  express  luciferase,  but  are 
sensitive  to  the  cleavage  of  inserted  sod1  fragment  by 
RNAi which causes the loss of poly A thus the degradation 
of  luciferase  mRNA.  For  testing  RNAi  efficacy,  either 
sense-target or antisense-target vector was co-transfected 
with  Renilla  luciferase  vector  (pRL-TK,  Promega)  plus 
siRNA or the shRNA-synthesizing vectors into HEK293 
cells  in  96-well  plates  in  quadruplicate  using 
Lipofectamine  2000  reagent  (Invitrogen).  Twenty  four 
hours after the transfection, cells were lysed with 20 µl 
Passive Lysis Buffer (Promega). Ten µl lysate from each 
well  was  transfer  into  a  well  in  a  strip  (Thermo 
labsystems)  and  measured  with  a  Veritas  microplate 
luminometer  (Turner  Biosystem).  The  luminescence 
intensity  ratio  (Firefly/Renilla  luciferase)  was  used  for 
measuring the RNAi efficacy. 
 
Northern blotting 
One  µg  of  each  of  the  shRNAs  was  transfected  into 
HEK293 cells in 6-well plates.  Cells were harvested 24 hr 
post-transfection and the total RNA was extracted with Tri 
Reagent  (Molecular  Research  Center).  Ten  µg  of  total 
RNA  was  loaded  onto  a  mini  15%  (w/v)  denaturing 
polyacrylamide gel. The separated RNAs were transferred 
onto  a  BrightStar-Plus  nylon  membrane  (Ambion)  and 
cross-linked with UV. 
32P-labeled sense or antisense 21 nt 
synthetic RNAs  were  used as  probes for  detecting  their 
complementary RNA strands. The radioactive RNA bands 
were read with Fuji Phosphor Imaging system FLA-5000 
(Fuji Medical Systems). 
 
RESULTS AND DISCUSSION 
 
Designed  asymmetry  switches  strand  preference  and 
enhances the RNAi efficacy of the desired strand 
Natural  siRNAs  (with  perfectly  complementary  double 
strands)  often  have  unfavorable  strand  asymmetry.    For 
example,  of  the  three  siRNAs  that  we  used  previously 
against human Cu, Zn superoxide dismutase (sod1) gene 
(Ding  et  al,  2003),  one  (P10)  silenced  the  sense  strand 
target  (ss-target),  the  sod1  mRNA,  better  than  the 
antisense  strand  target  (as-target),  thus  having  a  strand 
specificity  favoring  ss-target;  the  other  two  (P9,  P11) 
actually  silenced  the  as-target  better  than  the  ss-target, 
indicating  an  unfavorable  strand  specificity  toward  as-
target (Figure 1). As expected, the ones that preferentially 
silenced  the  as-target  silenced  the  ss-target  relatively 
inefficiently, with the half-inhibitory concentration (IC50) 
against the ss-target at ~2nM for the P9 and 5nM for the 
P11, compared with those against the as-target at 0.07nM 
and  0.1nM,  respectively.    Thus,  P9  and  P11  were  poor 
candidates of natural siRNAs. 
 
 
 
 
 
Figure 1. Asymmetric siRNAs.  P9, P10 and P11 are 21nt 
siRNAs targeting the same region of human sod1 mRNA.  The 
sequence of P11 is shown in Fig. 2A.  P9 and P10 target the sod1 
sequences 2- and 1-nt shifted toward the 5’ of the sod1 mRNA, 
respectively 28.  Even though the three siRNAs target sequences 
only 1nt shifted from each other, their strand preference are very 
different, with P9 and P11 favoring the anti-sense strand target 
and P10 favoring the sense strand target. All data points are 
normalized to the luciferase activity in cells transfected with 
luciferase constructs but without siRNA and means of four 
experiments. Standard deviations are in the range of 1.4%-19% 
of the means and are omitted from the figure for clarity. 
 
 
To  determine  whether  the  inefficient  siRNAs  could  be 
converted  into  efficient  ones,  we  took  one  of  the 
inefficient  siRNAs,  P11  (Figure  2A),  as  a  test  model.  
Based  on  the  asymmetry  rule,  we  destabilized  the  base 
pairing at the 5’ of the anti-sense strand of the siRNA (as-
siRNA) by placing mismatches or an A:U pair at that end  
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(Figure 2A, S1-S3). Although P11 naturally favored the 
as-target  (Figure  2B,  see  P11),  destabilizing  the  base 
pairing at the 5’ of the as-siRNA converted it to favoring 
sense  target  inhibition  (Figure  2B,  S1-S3).  Conversely, 
destabilizing base pairing at the 5’ of the sense strand of 
the  siRNA  (ss-siRNA)  accentuated  the  preference  to 
silencing the as-target (Figure 2B, A1-A3). Furthermore, 
destabilizing base pairing by replacing G:C with I:C at one 
end  or  the  other  similarly  switched  strand  preferences 
(Figure 2B, IA, IS). If G:C at both ends are converted to 
I:C, the strand preference returned to the pattern of the P11 
(Figure 2B, IS/IA). These changes are consistent with the 
predictions by the asymmetry rule. 
 
In  order  to  characterize  the  effects  of  the  designed 
asymmetry quantitatively, we transfected the ss- and as-
targets with different doses of siRNAs. The original P11 
silenced the as-target maximally by 81%, with the IC50 at 
0.1nM.  In contrast, it silenced the sense target maximally 
by  only  60%,  with  IC50  at  5nM  (Figure  3,  P11).    By 
destabilizing  the  base  pairing  at  the  5’  end  of  the  as-
siRNA,  the  siRNA  silenced  the  as-target  maximally  by 
only  56%,  with  an  atypical  dose-response  curve  that 
reached  the  maximal  silencing  at  2nM  of  siRNA  and 
poorer silencing at the higher concentrations; in contrast, 
this siRNA silenced the sense target maximally by 79%, 
with the IC50 at ~0.5nM (Figure 3, S2), a considerable 
improvement  compared  with  the  original  P11.  Thus, 
compared  with  the  original  P11,  weakening  the  base 
pairing  at  the  5’  of  the  as-siRNA  reduced  the  RNAi 
efficiency  against  the  as-target  and  enhanced  the  RNAi 
efficiency against the ss-target. Conversely, weakening the 
base pairing at the other end produced the reverse effect, 
enhancing  the  maximal  silencing  of  the  as-target  while 
preventing silencing of the sense target completely (Figure 
3, A2).  If base pairing was weakened at both ends of the 
siRNA, the silencing pattern of the target reverted to the 
original P11 (Figure 3, S2/A2).  These results support the 
predictions by  the  asymmetry  rule  and  indicate that  the 
asymmetry rule can be applied to increase the repertoire of 
siRNA targeting sites. 
 
Application of the asymmetry rule in shRNAs enhances 
strand specificity and efficacy 
shRNAs with either a 19 or 21 nt stem are commonly used 
in  the  literature.  To  discover  the  optimal  strategy  to 
incorporate the asymmetry rule in the design of shRNA, 
we first tested shRNAs with 19 nt stems with a mismatch 
placed within the first four nucleotides of either end of the 
shRNA stem (Figure 4A).  In order to eliminate the effects 
of mismatches, we used the targets that perfectly match the 
siRNA strand under the test. The shRNA with two strands 
of  the  stem  perfectly  matched  shows  symmetrical 
silencing  efficacy  (Figure  4B,  P11-19).  Mismatches  at 
positions 1 and 2 from the 5’ of the sense strand (Figure 
4A, A1-19, A2-19) enhanced the silencing of the as-target 
while  mildly  weakened  the  silencing  of  the  ss-target 
(Figure 4B, A1-19, A2-19), as predicted by the asymmetry 
rule. However, mismatches at positions 3 and 4 from the 
5’ of the sense strand (Figure 4A, A3-19, A4-19) enhanced 
the  silencing  efficacy  against  the  ss-target  and  did  not 
change the silencing efficacy of the as-target (Figure 4B, 
A3-19, A4-19), suggesting that mismatches in these two 
positions of the shRNA with 19 nt stem do not follow the 
asymmetry rule. 
 
A mismatch at position 1 from the 5’ end of the as-shRNA 
stem  (Figure  4A,  S1-19)  also  did  not  conform  to  the 
asymmetry  rule.    While  it  did  not  change  the  silencing 
efficiency  of  the  as-target,  it  actually  compromised 
silencing  of the ss-target (Fig. 4B, S1-19) – contrary to 
what was expected by the asymmetry rule. Mismatches at 
positions  2  and  3  from  the  5’  of  the  as  shRNA  stem 
(Figure 4A, S2-19, S3-19) did not enhance the silencing 
efficacy against the ss-target, though the silencing of the 
as-target  was  diminished  (Figure  4B,  S2-19,  S3-19).  A 
mismatches at position 4 from the 5’ end of the as shRNA 
stem  (Figure  4A,  S4-19)  did  not  affect  the  silencing 
efficacy against either the ss- or as-target (Figure 4B, S4-
19).  Overall, most of the mismatches created at either end 
of the stem  poorly conformed to the asymmetry rule in 
their silencing efficacy. 
 
shRNAs mimic pre-miRNAs in their structure, processing 
and function.  Most pre-miRNAs have stems longer than 
21-nt in length (Griffiths-Jones, 2004).  From these stems 
miRNA duplexes, including those that are asymmetric, are 
produced (Kim, 2005).  Thus, shRNAs with stems 21-nt or 
longer might be processed better after incorporation of the 
asymmetry rule.  To test this we designed shRNAs with 
21-nt stems and with weakened base pairing (mismatches) 
at  each  of  the  positions  1-4  at  both  ends  of  the  stem 
(Figure 5A). We cotransfected each of these plasmids that 
synthesize the shRNAs with the plasmids that synthesize 
the sense or antisense targets and determined their RNAi 
efficacy. 
 
The P11 shRNA had similar strand preference as the P11 
siRNA.  It silenced the as-target better than the ss-target 
(Figure  5B,  P11-21).  When  the  mismatched  base  pairs 
were  placed  at  the  5’  of  the  ss-shRNA,  the  strand 
preference to the as-target was accentuated at positions 1 
and 2 (Figure 5B, A1-21, A2-21), but reduced at position 3 
and 4 (Figure 5B, A3-21, A4-21).  Conversely, when the 
mismatches  were  placed  at  the  5’  of  the  as-shRNA  at 
positions 1-4, the strand preference is reversed from the 
original P11-21; the shRNA silenced the ss-target better 
than the as-target (Figure 5B, S1-21 to S4-21), although at 
the  position  4,  the  strand  preference  diminished.  We 
conclude  that  the  best  weak  base  pairing  position  for 
generating favorable strand preference is at position 2 of 
the  sense  strand  (A2-favoring  antisense  target)  and 
position  3  of  the  antisense  strand  (S3-favoring  sense 
target), because mismatches  at these positions  generated 
the largest degree of strand asymmetry. 
 
Previous  studies  using  Drosophila  embryo  extract 
demonstrated that the fate of the two strands in siRNA is 
different during RISC assembly. R2D2 acts as a sensor for 
the asymmetry of the siRNA duplexes and  binds to the 
thermodynamically stable end.  Dicer then binds the other 
end that is less  stable in its base pairing (Tomari et al, 
2004).  This  results  in  the  favored  strand  being 
incorporated  into  RISC  and  mediates  RNAi,  and  the 
opposite  strand  being  destroyed  (Schwarz  et  al,  2003; 
Matranga et al, 2005). The switch of the RNAi efficacy of 
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Figure 2. Natural strand preference can be designed by placing mismatches at the 5’ end of the siRNA strand desired to be the 
preferred strand to go into the RISC.  (A) Sense and antisense target sequences that were inserted into the 3’ UTR (top left), P11 
siRNA and its variations with mismatches placed at either end of the siRNA.  (B) Silencing efficacy of various siRNAs.  Notice that 
the sense strand of siRNA and antisense strand of the target are coded red and the antisense strand of siRNA and the sense strand of 
the target are coded black.  All data values were normalized with the target transfection without siRNA.  Each bar represents the 
average from 4 experiments.  Error bars represent standard deviations. 
 
 
 
S1
5’-GAGACUUGGGCAAUGUGAAdTdT-3’
******************
3’-dTdTCUCUGAACCCGUUACACUG-5’
S2
5’-GAGACUUGGGCAAUGUGACdTdT-3’
******************
3’-dTdTCUCUGAACCCGUUACACUU-5’
S3
5’-GAGACUUGGGCAAUGUGAAdTdT-3’
*******************
3’-dTdTCUCUGAACCCGUUACACUU-5’
A1
5’-GAGACUUGGGCAAUGUGACdTdT-3’
******************
3’-dTdTAUCUGAACCCGUUACACUG-5’
A2
5’-UAGACUUGGGCAAUGUGACdTdT-3’
******************
3’-dTdTCUCUGAACCCGUUACACUG-5’
A3
5’-UAGACUUGGGCAAUGUGACdTdT-3’
*******************
3’-dTdTAUCUGAACCCGUUACACUG-5’
IA
5’-IAGACUUGGGCAAUGUGACdTdT-3’
*******************
3’-dTdTCUCUGAACCCGUUACACUG-5’
IS
5’-GAGACUUGGGCAAUGUGACdTdT-3’
*******************
3’-dTdTCUCUGAACCCGUUACACUI-5’
IAIS
5’-IAGACUUGGGCAAUGUGACdTdT-3’
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Figure 3. Designed asymmetric siRNA improves the RNAi efficacy of the desired strand and decreases the RNAi efficacy of the 
undesired strand.  The sequences of P11, S2 and A2 siRNAs are shown in Figure 2A. The siRNA A2/S2 were generated by annealing 
the sense strand of A2 siRNA with the antisense strand of the S2 siRNA (see Figure 2A).  All data points were normalized as 
described in Figure 1.   
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Figure 4. The strand preference of shRNAs with 19nt stem are not predicted by the asymmetry rule. (A) Sequences of shRNAs with 
19 nt stem.  Mismatches were placed at the first 4 positions of either strand of the stems. (B) The silencing efficacy of sense and 
antisense target by the dual luciferase assay.  All the targets, including both the sense and antisense strands, perfectly complement 
their respective siRNA strands. 
 
 
the two strands depending on the strand asymmetry in the 
shRNAs  suggested  that  this  might  also  be  the  case  in 
mammalian cells (Figure 6A). To experimentally test this 
we  performed  northern  blot  analysis  on  RNA  extracted 
from cells transfected with the shRNA-expressing vectors. 
We  could  detect  the  shRNAs  produced  by  all  three 
constructs (Figure 6B).  The shRNAs were processed to 
siRNA.  Both  strands  of  siRNA  from  the  P11  construct 
were detectable.  However, only the favored strand could 
be detected from the S3 and A2 constructs (Figure 6B).  
This  result  is  consistent  with  those  obtained  using  the 
Drosophila  embryo  extracts  (Tomari  et  al,  2004).  The 
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a  recent  experiment  demonstrated  that  in  Drosophila, 
Louquacious (Loqs) binds to miRNA and this binding is 
required for Dicer-1 processing of miRNAs (Forstemann 
et al, 2005). In humans, a Loqs homolog TRBP performs 
the similar roles (Chendrimada et al, 2005). Both Loqs and 
TRBP are dsRNA binding proteins similar to R2D2, and 
thus, could act as an asymmetry sensor for  miRNAs  or 
shRNAs. 
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Figure 5. The strand preference of shRNAs with 21nt stem are well predicted by the asymmetry rule.  (A) Sequences of shRNAs 
with 21 nt stem.  Mismatches were placed at the first 4 positions of either strand of the stems.  (B) The silencing efficacy of the sense 
and antisense target were assayed by the dual luciferase assay.  All the targets, including both the sense and antisense strands, 
perfectly complement their respective siRNA strands. 
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Figure 6. Designed asymmetric shRNAs were processed as predicted by the asymmetry rule.  (A) Schematic processing of shRNA 
as predicted by the asymmetry rule.  The thickness of the arrows indicates the degree of preference of that siRNA strand being 
incorporated into the RISC and thus being preserved.  (B) Northern blot detecting shRNA and processed siRNA strands.  In each 
lane, total RNA (10 µg) from HEK293 cells transfected with the indicated shRNA constructs was loaded.  The blots were detected 
using either the sense or the antisense RNA probes. 
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Figure 7. A mismatch at the 3rd position of the strand distal to the loop optimally produces shRNAs with favorable strand 
preference.  Three additional sets of shRNAs with no mismatches, mismatches placed at A2 or S3 positions (A) were tested for their 
silencing efficacy to either the sense or the antisense targets (B).  All the targets, including both the sense and antisense strands, 
perfectly complement their respective siRNA strands. 
 
 
generate favorable strand preference in other shRNAs? To 
answer  this  question,  we  constructed  three  additional 
shRNAs  and  placed  mismatches  at  the  A2  and  S3 
positions (see Figure 7A). The original shRNAs silenced 
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(Figure  7B,  Or).  Placing  a  mismatch  at  position  A2 
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three  shRNAs,  although  the  magnitude  of  these  change 
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(Figure 7B, A2). On the other hand, placing a mismatch at 
S3  increased  the  silencing  efficacy  against  the  ss-target 
and decreased the silencing efficacy against the as-target 
(Figure 7B, S3). Based on these results, we conclude that a 
mismatch placed at S3 position most consistently enhances 
the strand specificity and RNAi efficacy. This design of 
asymmetric shRNAs could be used to generate effective 
shRNA  viral  vectors  in  silencing  dominant,  gain-of-
function gene mutations for gene therapy. 
 
CONCLUSIONS 
 
• Weakening  the  base  pairing  at  the  end  of  naturally 
symmetric  siRNA  effectively  converts  the  siRNA  into 
asymmetric siRNA, which enhances not only the strand 
specificity but also the efficacy of siRNA. 
 
• The incorporation of mismatch in the design of shRNA 
with 21 nt stem conforms to the asymmetry rule while 
the same strategy is not applicable to shRNA with 19 nt 
stem.  Unlike  siRNA,  shRNA  demonstrates  the  best 
asymmetry when a mismatch is placed at the position 2 
of antisense strand or position 3 of sense strand instead 
of position 1.   
 
• Asymmetrically designed siRNAs and shRNAs improve 
the gene silencing of intended targets and minimize the 
off-target effect, thus could be used in gene therapy of 
diseases  caused  by  dominant,  gain-of-function  gene 
mutations. 
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